Carl Atkinson to Receptors, Complement 3b
This is a "connection" page, showing publications Carl Atkinson has written about Receptors, Complement 3b.
Connection Strength
0.702
-
Characterization of Novel P-Selectin Targeted Complement Inhibitors in Murine Models of Hindlimb Injury and Transplantation. Front Immunol. 2021; 12:785229.
Score: 0.190
-
Increasing the efficacy and safety of a human complement inhibitor for treating post-transplant cardiac ischemia reperfusion injury by targeting to a graft-specific neoepitope. J Heart Lung Transplant. 2021 10; 40(10):1112-1121.
Score: 0.185
-
Targeting pathogenic postischemic self-recognition by natural IgM to protect against posttransplantation cardiac reperfusion injury. Circulation. 2015 Mar 31; 131(13):1171-80.
Score: 0.119
-
Complement-dependent P-selectin expression and injury following ischemic stroke. J Immunol. 2006 Nov 15; 177(10):7266-74.
Score: 0.067
-
Targeted complement inhibition by C3d recognition ameliorates tissue injury without apparent increase in susceptibility to infection. J Clin Invest. 2005 Sep; 115(9):2444-53.
Score: 0.062
-
A new treatment for neurogenic inflammation caused by EV71 with CR2-targeted complement inhibitor. Virol J. 2012 Nov 23; 9:285.
Score: 0.025
-
Modulation of protective T cell immunity by complement inhibitor expression on tumor cells. Cancer Res. 2008 Aug 15; 68(16):6734-42.
Score: 0.019
-
A complement C3 inhibitor specifically targeted to sites of complement activation effectively ameliorates collagen-induced arthritis in DBA/1J mice. J Immunol. 2007 Dec 01; 179(11):7860-7.
Score: 0.018
-
Complement plays an important role in spinal cord injury and represents a therapeutic target for improving recovery following trauma. Am J Pathol. 2006 Sep; 169(3):1039-47.
Score: 0.017